OBESITY AND CARDIOVASCULAR DISEASE: A SYSTEMATIC REVIEW
Keywords:
Cardiovascular Disease, Energy, Obesity, SedentaryAbstract
The pathophysiology of obesity includes a function for the equilibrium between the number of calories consumed and the quantity of energy expended, which is then followed by a resetting of body weight. On the other hand, this is not as straightforward as solving an equation, and there are a number of secondary processes that contribute to this difficult condition. It is believed that obesity is a state of inflammation because obese people have a greater amount of fat tissue and a lower level of adiponectin. This means that obese people are less able to stop the processes that generate inflammation, which in turn keeps the inflammation going. This adipocyte dysregulation adds to the imbalance of homeostasis as well as pro- and anti-inflammatory mechanisms in the body, which in turn contributes to metabolic difficulties caused by obesity as well as vascular damage that leads to changes in cardiometabolic function. The structure and function of the cardiovascular system, as well as the hemodynamics of the blood, are all severely influenced by obesity. Obesity also has a negative impact on the metabolic processes of the body. When a person is obese, their total blood volume as well as their cardiac output go up, which also leads to an increase in the amount of work that their heart has to do. Patients who are obese often have a higher cardiac output but a lower level of total peripheral resistance at any given level of arterial pressure. This is because obesity typically causes a decrease in total peripheral resistance. Previous research has demonstrated that patients or individuals with a body mass index (BMI) that is greater than 25, have a high risk connected with the risk of cardiovascular disease (CVD). In addition to this, the strength of this connection grows with advancing age.
References
Organization WH. Overweight and obesity. 2020;
Collaboration NCDRF. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19· 2 million participants. Lancet. 2016;387(10026):1377–96.
Upadhyay J, Farr O, Perakakis N, Ghaly W, Mantzoros C. Obesity as a disease. Med Clin. 2018;102(1):13–33.
Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism.
;92:98–107.
Akil L, Ahmad HA. Relationships between obesity and cardiovascular diseases in four southern states and Colorado. J Health Care Poor Underserved. 2011;22(5):61–72.
Wahl S, Drong A, Lehne B, Loh M, Scott WR, Kunze S, et al. Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity. Nature. 2017;541(7635):81–6.
Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113(6):898–918.
Mathew B, Francis L, Kayalar A, Cone J. Obesity: effects on cardiovascular disease and its diagnosis. J Am Board Fam Med. 2008;21(6):562–8.
Bastien M, Poirier P, Lemieux I, Després J-P. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis. 2014;56(4):369–81.
Rothman KJ. BMI-related errors in the measurement of obesity. Int J Obes. 2008;32(3):S56–9.
Staplin N. Confounding is not the only bias influencing associations of adiposity with cardiovascular disease. Eur Heart J. 2018;39(17):1521.
Zhang C, Rexrode KM, Van Dam RM, Li TY, Hu FB. Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality: sixteen years of follow-up in US women. Circulation. 2008;117(13):1658–67.
Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet.
;364(9438):937–52.
Yang L, Wu H, Jin X, Zheng P, Hu S, Xu X, et al. Study of cardiovascular disease prediction model based on random forest in eastern China. Sci Rep. Maret 2020;10(1):5245.
Barroso TA, Marins LB, Alves R, Gonçalves ACS, Barroso SG, Rocha G de S. Association of central obesity with the incidence of cardiovascular diseases and risk factors. Int J Cardiovasc Sci. 2017;30:416–24.
Bakhtiyari M, Kazemian E, Kabir K, Hadaegh F, Aghajanian S, Mardi P, et al. Contribution of obesity and cardiometabolic risk factors in developing cardiovascular disease: a population-based cohort study. Sci Rep
[Internet] 2022;12(1):1544. Tersedia pada: https://doi.org/10.1038/s41598-022-05536-w
Bode ED, Mathias KC, Stewart DF, Moffatt SM, Jack K, Smith DL. Cardiovascular Disease Risk Factors by BMI and Age in United States Firefighters. Obesity [Internet] 1 Juli 2021;29(7):1186–94. Tersedia pada: https://doi.org/10.1002/oby.23175
Schwartz MW, Seeley RJ, Zeltser LM, Drewnowski A, Ravussin E, Redman LM, et al. Obesity pathogenesis: an endocrine society scientific statement. Endocr Rev. 2017;38(4):267–96.
Vassallo J. Pathogenesis of obesity. 2007;
Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al. Emerging Risk Factors Collaboration C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132–40.
Ridker PM, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. Oktober
;39(38):3499–507.
Alpert MA. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci.
;321(4):225–36.
Lavie CJ, Milani R V, Ventura HO. Obesity and Cardiovascular Disease: Risk Factor, Paradox, and Impact of Weight
Loss. J Am Coll Cardiol [Internet] 2009;53(21):1925–32. Tersedia pada: https://www.sciencedirect.com/science /article/pii/S0735109709007463
Elagizi A, Kachur S, Carbone S, Lavie CJ, Blair SN. A Review of Obesity, Physical Activity, and Cardiovascular Disease. Curr Obes Rep [Internet] 2020;9(4):571–81. Tersedia pada: https://doi.org/10.1007/s13679-020-00403-z
Wilson PWF, D’Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162(16):1867–72.
Das SR, Alexander KP, Chen AY, Powell-Wiley TM, Diercks DB, Peterson ED, et al. Impact of body weight and extreme obesity on the presentation, treatment, and in-hospital outcomes of 50,149 patients with ST-segment elevation myocardial infarction: results from the NCDR (National Cardiovascular Data Registry). J Am Coll Cardiol. 2011;58(25):2642–50.
Jamil G, Jamil M, AlKhazraji H, Haque A, Chedid F, Balasubramanian M, et al. Risk factor assessment of young patients with acute myocardial infarction. Am J Cardiovasc Dis. 2013;3(3):170.
Alpert MA, Omran JAD, Bostick BP. Effects of obesity on cardiovascular hemodynamics, cardiac morphology, and ventricular function. Curr Obes Rep. 2016;5(4):424–34.
Kenchaiah S, Evans JC, Levy D, Wilson PWF, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347(5):305–13.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
